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P. De Rango *
Unit of Vascular and Endovascular Surgery, Hospital S Maria Misericordia, Perugia, ItalyBetter understanding of mechanisms behind carotid ste-
nosis has challenged the traditional approach to carotid
endarterectomy (CEA) as the gold standard for stroke pre-
vention in symptomatic and asymptomatic carotid disease.
For symptomatic patients, the high risk of new early
embolic recurrence suggested not delaying surgical removal
of the carotid embolic plaque for more than 2 weeks after
the acute neurological event. For symptom-free patients
management of the carotid stenosis by surgery has been
even more debated because of the high likelihood of
decreased stroke risks with systematic and intensive use of
modern medical therapy including antiplatelets, statins, and
antihypertensive drugs. However, in supporting this modern
approach to carotid stenosis the sudden and often unpre-
dictable nature of its acute manifestation (i.e. the emboli-
zation from a “high-risk” carotid plaque resulting in stroke)
for both already or never symptomatic carotid patients re-
mains a challenge. Emerging evidence has highlighted the
role of inﬂammatory markers, such as vascular cell adhesion
molecules (VCAMs), selectin, chemokines, and proteases
(e.g. metalloproteinases), for their potential in triggering a
previous quiescent atherosclerotic plaque. In this perspec-
tive, cell-derived membrane microparticles (MPs) are
among the newest biomarkers suggested for their effect on
triggering atherosclerotic plaque.1e3 MPs, also known as
“microvescicles” or “ectosomes”,2 are large (50e1000 nm
diameter) extracellular vesicles surrounded by a phospho-
lipid bilayer that are released into extracellular space or
circulation by direct budding from the plasma membrane of
multiple lines of activated cells including platelets, endo-
thelial cells, and leukocytes. In this issue of the European
Journal of Vascular and Endovascular Surgery, Wekesa
et al.4 performed a caseecontrol pilot study analyzing levels
of endothelial MPs and platelet MPs in addition to other
atherosclerotic molecular biomarkers in plasma from 42
patients undergoing CEA for symptomatic (n ¼ 37) and
asymptomatic (n ¼ 4) carotid stenosis patients (cases) and
from 73-age and sex-matched patients without carotidDOI of original article: http://dx.doi.org/10.1016/j.ejvs.2014.08.007
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http://dx.doi.org/10.1016/j.ejvs.2014.08.020disease used as controls. The excised carotid plaques from
the cases group were also analyzed with immunohisto-
chemistry and graded for stability according to the inﬂam-
matory cell inﬁltration in the plaque and cap and the
evidence of plaque rupture and surface thrombus as
deﬁned by Redgrave.5 Wekesa et al.4 found signiﬁcantly
higher levels of subsets of platelet MP and annexin Vþ MPs
in carotid stenosis patients than in controls (p < .05) while
the other soluble vascular inﬂammatory biomarkers tested
in the same study (soluble intercellular adhesion molecule
[sICAM-I], soluble vascular cell adhesion molecule [sVCAM-
I], and serum amyloid A [SAA]) did not signiﬁcantly differ.
Furthermore, annexin Vþ MP was independently associated
with carotid stenosis in multivariable model analysis. In
addition, endothelial MP subsets (but not any vascular, in-
ﬂammatory, or proteolytic molecular tested biomarker)
were found to be higher in unstable than in stable plaque
patients and the association was conﬁrmed in univariate
and multivariable analyses.4
Although the message from Wekesa et al. may be rele-
vant, suggesting higher sensitivity of MP than other mo-
lecular biomarkers for predicting both the plaque instability
(endothelial MP) and the presence of advanced carotid
disease (platelet MPs), the results of the study should be
interpreted with caution.
As with most of the other literature studies testing bio-
markers related to the concept of “unstable/vulnerable”
plaque, the cross-sectional design in Wekesa study pre-
cluded evaluation of the true predictive utility of MPs as
biomarkers of clinical events.1
Furthermore, because the “unstable” plaque is not an
established medical diagnosis, the gold standard for reference
was based on the immunohistochemistry pattern of carotid
plaque stability; none of the plaques examined byWekesawas
documented to be responsible for cerebrovascular events.
Finally, biomarker research provides a powerful approach
to understanding the spectrum of cerebrovascular disease
and is expected to continue rapidly expand in the near
future. However, the complexity of biomarker research and
the need for speciﬁc laboratory tools and techniques do not
allow an extensive application in current everyday practice,
and the cost-effectiveness of this approach in identifying
high-risk carotid plaque remains debatable.
During the past few years an increasing number of his-
topathology, but especially more advanced molecular
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been developed to help identify what may affect the
“vulnerability” or “instability” of atherosclerotic plaque
leading to rupture and symptoms. Despite the growing
body of evidence supporting the current modern approach
to carotid surgery for stroke prevention, the precise
mechanisms that lead to embolization from a “high-risk”
carotid plaque resulting in stroke remain not adequately
understood. The research in this ﬁeld is still inadequate and
has failed to identify with certainty patients in whom
disruption of a vulnerable plaque is likely to result in a
clinical event. Regardless of the important contributions to
knowledge of carotid diseases from biomarkers such as
MPs, in the 21st century we do not know which of the
patients with carotid plaque will suffer an event or when
one will occur. The “unstable/vulnerable” plaque remains a
probabilistic diagnosis and not a deﬁnite entity.1 More and
more sound research is needed to understand how to best
manage surgery for symptomatic and asymptomatic carotid
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